BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sepracor, Inc. (SEPR) Release: New STEDESA(TM) Clinical Data Presented at American Epilepsy Society Annual Meeting in Boston


12/7/2009 10:04:40 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate; ESL) were presented during a scientific poster session at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters were presented on Dec. 5, 2009 and included data regarding safety and efficacy evaluations of STEDESA. These data were derived from the pooled results of three, placebo-controlled Phase III studies of STEDESA in which adult patients who had a history of at least four partial-onset seizures per month despite treatment with one to three concomitant antiepileptic drugs (AEDs) were randomized to 400 mg, 800 mg or 1200 mg of ESL or placebo.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->